Short answer
Travere Therapeutics, Inc. (TVTX) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the quarter ended September 30, 2026.
Travere Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Press release and accompanying financial information provided in Exhibit 99.1
- Results announcement gives investors the company’s latest operating and financial update
Item EX-99.1 · Exhibit EX-99.1
- Q3 U.S. net product sales $220.2M, up from $113.2M, with FILSPARI sales $200.2M and 120% year-over-year growth
- 1,932 new FILSPARI patient start forms, supporting commercial momentum across IgAN and the newly launched FSGS indication
- GAAP net loss $52.3M, or $0.55 per share, including $113.1M civorebrutinib acquired in-process R&D expense
- Cash, cash equivalents and marketable securities $471.8M, funding continued commercialization and pipeline development
- HARMONY Phase 3 topline results remain targeted for 2H 2027, while civorebrutinib U.S. IND submission is planned by year-end
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Travere Therapeutics, Inc. 8-K filings
Get the next TVTX 8-K as it lands
Follow TVTX for push alerts, or ask the research agent what this filing means.